BioTuesdays

Category - Markets

Senseonics
Markets

BTIG ups Senseonics PT to $4 from $3

BTIG raised its price target for Senseonics (NYSE American:SENS) to $4 from $3, saying the company’s new Patient Access Bridge program makes strategic sense, even though it caused Senseonics to lower its 2019 guidance...

March 13, 2019
Markets

SVB Leerink starts TCR2 Therapeutics at OP; PT $27

SVB Leerink launched coverage of TCR2 Therapeutics (NASDAQ:TCRR) with an “outperform” rating and $27 price target. The stock closed at $15.64 on March 8. TCR2 is a clinical-stage cell therapy company developing a...

March 11, 2019
Avedro
Markets

SVB Leerink starts Avedro at OP; PT $20

SVB Leerink initiated coverage of Avedro (NASDAQ:AVDR) with an “outperform” rating and $20 price target. The stock closed at $11.70 on March 8. Analyst Danielle Antalffy writes that the company’s key growth driver is...

March 11, 2019
Anchiano Therapeutics
Markets

Ladenburg starts Anchiano Therapeutics at buy; PT $20

Ladenburg Thalmann initiated coverage of Anchiano Therapeutics (NASDAQ:ANCN) with a “buy” rating and $20 price target. The stock closed at $7.72 on March 8. Anchiano is focused on applying its gene therapy technology as...

March 11, 2019
Gritstone Oncology
Markets

HCW starts Gritstone Oncology at buy; PT $17

H.C. Wainwright launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $17 price target. The stock closed at $11.64 on March 6. Gritstone is focused on developing novel neoantigen-targeting...

March 7, 2019
T2 Biosystems Logo
Markets

Canaccord recommends buying T2 Biosystems on weakness

Canaccord Genuity reiterated its “buy” rating and $10 price target for T2 Biosystems (NASDAQ:TTOO), saying, “We would buy on weakness.” The stock was quoted at $3.71, down 58 cents, or 13%, in afternoon trading on March...

March 5, 2019